All In Biotech

Free tool

FAERS Monitor: Fexinidazole

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214429 or its brand name (Fexinidazole, Fexinidazole). Reports on generic versions are filed under their own applications.

Reports

13

Serious

13

100% of reports

Hospitalization

5

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure6
  • anaemia3
  • pyrexia3
  • treatment failure3
  • asphyxia2
  • coma2
  • completed suicide2
  • headache2
  • pneumonia2
  • abdominal pain upper1
  • acute kidney injury1
  • acute pulmonary oedema1
  • african trypanosomiasis relapse1
  • agitation1
  • asthenia1

Reports by year received

View as table
YearReports
20213
20222
20241
20254
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asphyxia2396.3110.7443
acute pulmonary oedema1288.343.971
seizureSignal684.046.7415
coma268.019.074
treatment failureSignal358.621.7118
completed suicide238.810.941
anaemiaSignal325.49.449
agitation122.03.45
pyrexiaSignal314.05.225
acute kidney injury110.61.62
pneumonia210.02.89
abdominal pain upper17.91.21
headache25.21.43
asthenia14.30.70
african trypanosomiasis relapse10.00.0404,887

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.